Launch of the US Myeloma Network Aims to Transform Clinical Trials and Patient Access
The recent launch of the US Myeloma Network (USMN) by the International Myeloma Foundation (IMF) marks a significant milestone in the quest to combat multiple myeloma, a complex blood cancer. This initiative aims to create a national clinical research network, facilitating the acceleration of scientific discovery and improving patient access to groundbreaking therapies. With Johnson & Johnson acting as the inaugural industry collaborator, this network is set to reshape how clinical trials are conducted and how patients receive treatment.
Dr. S. Vincent Rajkumar, Chairperson of the IMF and a prominent oncologist at the Mayo Clinic, emphasized the necessity for swift and equitable access to innovative treatments. "The future of myeloma depends on our ability to bring scientific innovation to patients more quickly and more equitably," he stated. The US Myeloma Network will interlink leading academic centers, community oncology practices, and industry partners through a cohesive nationwide framework designed to minimize operational hurdles and boost patient participation.
One fundamental aim of the USMN is to enhance equity in clinical research. Historically, underrepresented populations have faced barriers to participating in clinical trials. The network plans to address this by partnering with communities to provide culturally responsive and linguistically appropriate educational resources. This strategy ensures that patients can confidently engage in research initiatives irrespective of their backgrounds or geographic locations.
Heather Cooper Ortner, President and CEO of IMF, emphasized the importance of patient involvement in advancing medical breakthroughs. "Every breakthrough in myeloma begins with a patient who participates in research," she noted. The US Myeloma Network's focus on inclusivity will broaden the horizons of clinical trials, allowing more patients to access promising new therapies faster.
Imran Khan, Vice President of U.S. Hematology Medical Affairs at Johnson & Johnson, expressed pride in supporting the network, highlighting the company’s commitment to improving outcomes for multiple myeloma patients through collaborative research efforts.
Strategically aligned with Sarah Cannon Development Innovations, the USMN leverages their expertise in complex oncology trials, reinforcing a robust research infrastructure that can expedite the launch of innovative studies. Marcy Vallone, Senior Vice President at Sarah Cannon Development Innovations, affirmed the collaborative link: "Together, we are creating more opportunities for patients and advancing the next generation of therapies for multiple myeloma."
For nearly four decades, the IMF has been a champion for patients affected by multiple myeloma, ceaselessly pursuing advancements in research and treatment. The US Myeloma Network is an evolution of this commitment, reimagining clinical research to enhance access to innovations and turning the promise of scientific discoveries into accessible treatments for patients.
Multiple myeloma, a cancer affecting plasma cells in the bone marrow, is characterized by multiple areas of tumor growth and can result in bone and kidney damage. Although progress in treatment has significantly improved survival rates, there is still much to be done. Notably, the incidence of multiple myeloma is notably higher among Black and African American populations, which underscores the need for this network's equitable access approach.
The launch of the US Myeloma Network represents an ambitious endeavor to revolutionize clinical trials and improve patient experiences. By prioritizing patient engagement, enhancing accessibility, and fostering partnerships across the healthcare spectrum, the network aims to hasten the journey from scientific discovery to real-world treatment—ultimately working towards a future where multiple myeloma can be cured. Through initiatives like this, the IMF reaffirms its role as a leader in the fight against this formidable disease and its unwavering commitment to improving the lives of those affected by myeloma.
To learn more about the US Myeloma Network and its initiatives, visit www.myeloma.org.
Dr. S. Vincent Rajkumar, Chairperson of the IMF and a prominent oncologist at the Mayo Clinic, emphasized the necessity for swift and equitable access to innovative treatments. "The future of myeloma depends on our ability to bring scientific innovation to patients more quickly and more equitably," he stated. The US Myeloma Network will interlink leading academic centers, community oncology practices, and industry partners through a cohesive nationwide framework designed to minimize operational hurdles and boost patient participation.
One fundamental aim of the USMN is to enhance equity in clinical research. Historically, underrepresented populations have faced barriers to participating in clinical trials. The network plans to address this by partnering with communities to provide culturally responsive and linguistically appropriate educational resources. This strategy ensures that patients can confidently engage in research initiatives irrespective of their backgrounds or geographic locations.
Heather Cooper Ortner, President and CEO of IMF, emphasized the importance of patient involvement in advancing medical breakthroughs. "Every breakthrough in myeloma begins with a patient who participates in research," she noted. The US Myeloma Network's focus on inclusivity will broaden the horizons of clinical trials, allowing more patients to access promising new therapies faster.
Imran Khan, Vice President of U.S. Hematology Medical Affairs at Johnson & Johnson, expressed pride in supporting the network, highlighting the company’s commitment to improving outcomes for multiple myeloma patients through collaborative research efforts.
Strategically aligned with Sarah Cannon Development Innovations, the USMN leverages their expertise in complex oncology trials, reinforcing a robust research infrastructure that can expedite the launch of innovative studies. Marcy Vallone, Senior Vice President at Sarah Cannon Development Innovations, affirmed the collaborative link: "Together, we are creating more opportunities for patients and advancing the next generation of therapies for multiple myeloma."
For nearly four decades, the IMF has been a champion for patients affected by multiple myeloma, ceaselessly pursuing advancements in research and treatment. The US Myeloma Network is an evolution of this commitment, reimagining clinical research to enhance access to innovations and turning the promise of scientific discoveries into accessible treatments for patients.
Multiple myeloma, a cancer affecting plasma cells in the bone marrow, is characterized by multiple areas of tumor growth and can result in bone and kidney damage. Although progress in treatment has significantly improved survival rates, there is still much to be done. Notably, the incidence of multiple myeloma is notably higher among Black and African American populations, which underscores the need for this network's equitable access approach.
The launch of the US Myeloma Network represents an ambitious endeavor to revolutionize clinical trials and improve patient experiences. By prioritizing patient engagement, enhancing accessibility, and fostering partnerships across the healthcare spectrum, the network aims to hasten the journey from scientific discovery to real-world treatment—ultimately working towards a future where multiple myeloma can be cured. Through initiatives like this, the IMF reaffirms its role as a leader in the fight against this formidable disease and its unwavering commitment to improving the lives of those affected by myeloma.
To learn more about the US Myeloma Network and its initiatives, visit www.myeloma.org.
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.